Demand for erectile dysfunction drugs has been strong in the recent past. Lifestyle diseases such as hypertension, diabetes, etc. are a major reason for erectile dysfunction. Stress and sedentary lifestyles are triggering the onset of lifestyle diseases. Medications for treating these conditions also cause erectile dysfunction.
Awareness regarding erectile dysfunction and drugs for treating it has augmented due to various factors. This has fueled demand for the market. The erectile dysfunction drugs market was worth about USD 5 billion in 2014. It could benefit from governmental reforms and awareness campaigns in Asia Pacific and Latin America.
Full research report on erectile dysfunction drugs market analysis:
Other favorable factors for the market include improving healthcare infrastructure, economic development, and growing target population. Medical innovations such as new molecule combinations and drug delivery techniques (creams, pellets, etc) present future opportunities. These trends assure higher drug efficacy and performance.
Despite the aforesaid drivers, the market will witness a downfall over the forecast period (2015 to 2022). By 2022, it would be valued only around USD 3 billion. This could be attributed to forthcoming expiration of leading drug patents. Other inhibitors of the erectile dysfunction drugs market comprise threat from counterfeit products, narrowing insurance coverage, bigger risk of sexually transmitted diseases, and social stigma in developing regions.
Request for sample of this research report:
The market is segregated into products and regions. Some of the product segments encompass Viagra (sildenafil citrate), Zydena (udenafil), and Cialis (tadalafil). Stendra/Spedra (avanafil), Vitaros (alprostadil cream), Levitra/Staxyn (vardenafil), and others are the rest. Viagra is the most-demanded product. It accounted for close to 48% of the global revenues in 2014 and is often the first line of treatment.
Viagra’s dominance is challenged by Cialis and Levitra. Its patent would expire in the U.S. in 2019. Yet, Viagra is estimated to control 30% of the erectile dysfunction drugs market by 2022. This is due to its strong brand identity and customer loyalty. Zydena, Stendra/Spedra, and Vitaros would grab greater shares after Cialis and Levitra patents expire in 2017 and 2018, respectively.
Regional segments comprise North America, Asia Pacific, Europe, and Rest of the World (RoW). North America led the market in 2014, while Europe was placed second. The former benefits from well-established healthcare systems, huge demand, and extensive medical research. Asia Pacific is anticipated to grow at a CAGR of 2.5% during the forecast period.
Key competitors in the global erectile dysfunction drugs market are Bayer AG, Pfizer Inc., Eli Lily and Company, and Apricus Biosciences Inc. The time period post expiry of patents can be marked by mergers, acquisitions, & collaborations.
View more reports of this category by Grand View Research at:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States